plegre

Plegre is a rare genetic disorder characterized by the progressive degeneration of the central nervous system, leading to severe cognitive decline and motor dysfunction. It is caused by mutations in the PLEKHG5 gene, which encodes a protein involved in the regulation of the actin cytoskeleton. The disorder is typically diagnosed in infancy or early childhood, with symptoms including delayed motor development, seizures, and microcephaly.

The progression of Plegre is rapid, with patients usually developing severe intellectual disability and loss of previously acquired skills within the first decade of life. Motor symptoms may include spasticity, dystonia, and rigidity, which can lead to contractures and difficulty with mobility. Seizures are common and may be resistant to antiepileptic medications.

There is no cure for Plegre, and management is primarily supportive. Treatment focuses on addressing symptoms, such as antiepileptic drugs for seizures and physical therapy for motor function. Research into potential therapies, including gene therapy and small molecule inhibitors, is ongoing.

Plegre is a rare disorder, with an estimated prevalence of less than 1 in 100,000 live births. It is inherited in an autosomal recessive manner, meaning both copies of the PLEKHG5 gene must have mutations for the disorder to develop. Genetic counseling is recommended for families with a history of Plegre to help them understand the risk of passing the disorder to future children.

The prognosis for individuals with Plegre is poor, with most patients not surviving beyond the second decade of life. However, the exact lifespan can vary, and some individuals may live into their teens or early 20s. The disorder is typically diagnosed through genetic testing, which can identify mutations in the PLEKHG5 gene. Early diagnosis and intervention can help improve the quality of life for affected individuals and their families.